GlassScriptPhysician profile
Michael Moses Goodman
NPI 1619020179
$3,755.75
in general payments reported to CMS, 2019-2025
16 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $2,325 · 2021: $31.50 · 2023: $50.50 · 2024: $14.16 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $118 · Food and Beverage: $75.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $117.50 |
| Food and Beverage | $75.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $2,392.00 | 2020-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $1,206.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $61.00 | 2025 | Dupixent |
| Eisai INC. | $50.50 | 2023 | |
| Seagen INC. | $31.50 | 2021 | |
| Array Biopharma INC | $14.16 | 2024 | Braftovi, Mektovi |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.